MedTrace Logo

Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS

NCT04331613 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2020-04-02

No results posted yet for this study

Summary

A phase1/2, open label, dose escalation, safety and early efficacy study of CAStem for the treatment of severe COVID-19 associated with or without ARDS.

Conditions

  • COVID-19
  • Acute Respiratory Distress Syndrome
  • Virus; Pneumonia
  • Acute Lung Injury

Interventions

BIOLOGICAL

CAStem

CAStem will be administered intravenously.

Sponsors & Collaborators

  • Beijing YouAn Hospital

    collaborator OTHER

  • Chinese Academy of Sciences

    lead OTHER_GOV

Principal Investigators

  • Zhou Qi, Doctor · Institute of Zoology, Chinese Academy of Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-27
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04331613 on ClinicalTrials.gov